

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 June 2023 (29.06.2023)



(10) International Publication Number
WO 2023/118875 A1

(51) International Patent Classification:

C07D 237/30 (2006.01) C07D 498/04 (2006.01)
C07D 401/06 (2006.01) A61K 31/502 (2006.01)
C07D 403/06 (2006.01) A61P 3/00 (2006.01)
C07D 405/06 (2006.01) A61P 7/00 (2006.01)
C07D 405/14 (2006.01) A61P 37/00 (2006.01)
C07D 413/06 (2006.01) A61P 35/00 (2006.01)
C07D 417/06 (2006.01) C07D 403/14 (2006.01)
C07D 471/04 (2006.01)

(21) International Application Number:

PCT/GB2022/053355

(22) International Filing Date:

22 December 2022 (22.12.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

21216843.9 22 December 2021 (22.12.2021) EP
22177827.7 08 June 2022 (08.06.2022) EP
PCT/GB2022/052781
04 November 2022 (04.11.2022) GB

(71) Applicant: **SITRYX THERAPEUTICS LIMITED**
[GB/GB]; 101 Bellhouse Building, Magdalen Centre, The
Oxford Science Park, Oxford OX4 4GA (GB).

(72) Inventors: **DAVID, Cousin**; c/o Sygnature Discovery Lim-
ited, The Discovery Building Biocity, Pennyfoot Street,
Nottingham Nottinghamshire NG1 1GR (GB). **OSCAR,**
Barba; c/o Sitryx Therapeutics Limited, 101 Bellhouse
Building, Magdalen Centre, The Oxford Science Park, Ox-
ford OX4 4GA (GB).

(74) Agent: **ALISON, Kinch** et al.; Sagittarius IP, Marlow In-
ternational, Parkway, Marlow Buckinghamshire SL7 1YL
(GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,


DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS



(57) Abstract: The invention relates to a compound of formula (I) which is 6-((1H-pyrazol-4-yl)sulfonyl)-2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)-one; or a salt and/or solvate thereof; and to its use in treating or preventing an inflammatory disease, a disease associated with an undesirable immune response, cancer, obesity, a diabetic disease or a blood disorder.



WO 2023/118875 A1